As OKLO gears up to report second-quarter earnings, let's find out how the expectations stack up. Also, know how to play the stock ahead of results.
News
High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Sandisk has massively outperformed the broader market over the past year, and analysts are highly optimistic about the stock’s prospects.

<body><p>STORY: :: Novo Nordisk</p><p>'''Right now, the market isn't convinced that Novo Nordisk pipeline of experimental drugs is robust enough to fight against Lilly.''</p><p>:: How is Novo Nordisk future proofing as investors worry about pipeline?</p><p>:: August 5, 2026</p><p>:: Maggie Fick, European Pharma Industry Correspondent </p><p>''The drugmaker on Tuesday raised its full year profit and sales outlook, but investors are less focused on the numbers. They did look at the weaker than expected sales for its new Wegovy pill, and they're more focused on what the answer that the company has is to this question of the expirations of the patents for the company's key drugs. ''</p><p>'''So the name of the game now really is the medicines that Novo Nordisk is testing right now in trials. And also on Tuesday, Novo reported a trial failure for one of its next generation obesity drugs, obesity and diabetes drugs, CagriSema, and we think that's part of the reason that shares fell on these announcements.''</p><p>:: What is CEO Mike Doutsdar's response?</p><p>:: Novo Nordisk</p><p>''So Mike Doustdar acknowledged these recent trials setbacks, but he argued that they don't change the company's strategy. He says the answer is to move faster in research. He's been at the helm of the company now for a year. And he said one of the important steps he took was to combine research and development under one executive, and that that is helping that department move faster with trials. And he continues to say that failures are part of the pharmaceutical industry, that, trials are run with risks and so this is not unusual and they just have to keep moving. He said that it's important for Novo to stick to its strategy of bolt-on acquisitions to complement its own research and development. And he stressed that a transformational acquisition, a big merger, is not something on his agenda and that's for companies that have big problems.''</p></body>
Eli Lilly stock jumped Wednesday on a solid beat-and-raise thanks to its GLP-1 drugs, treatments for diabetes and obesity.
If you are looking for stocks that are well positioned to maintain their recent uptrend, Aehr Test Systems (AEHR) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.
CDW Corporation (NASDAQ:CDW) reported second-quarter results that exceeded Wall Street expectations for both earnings and revenue, but shares dropped more than 8% in pre-market trading as investors focused on weaker margins and higher restructuring costs. The technology solutions provider posted adjusted earnings of $2.
SpaceX Eyes Major Starship Milestone With First Attempt at Landing the Upper Stage
PKX, PARR, SBH, BIP and DINO stand out with attractive EV-to-EBITDA ratios and strong earnings outlook.
Rocket Lab Lands $397 Million Space Force Contract
S&P 500 and Dow Jones Industrial Average futures were on track to set another record high ahead of Wednesday's opening bell. Nasdaq 100 futures were also in the green, but lagged S&P 500 and Dow futures' gains.
In an exclusive interview with WardsAuto, Unifor National President Lana Payne shares her takeaways from recent negotiations with Ford — and what’s ahead.
Treasury yields held earlier overnight declines after the Treasury Department signaled–again–that it has no plans to increase the sizes of note-and-bond auctions for “at least the next several quarters.” The Treasury’s guidance, made as part of its quarterly refunding announcement, was the same that it has made for the past 11 quarters dating back to the start of 2024.
Individual stocks are sporting unusually high IV relative to the SPY
Morgan Stanley (MS) is leading a consortium of banks planning to refinance through bond sales $15 bi
OXY is poised for sharp Q2 growth, backed by debt cuts and cash flow, but commodity swings and a premium valuation cloud the setup.
Investing.com -- Jefferies downgraded Best Buy, a U.S. consumer electronics retailer to Hold from Buy, saying the market already reflects an optimistic outlook for second-quarter comparable sales while earnings upside beyond that could prove more limited amid softer consumer demand and rising cost pressures.
The manufacturer said its obesity medications Mounjaro and Zepbound were driving an acceleration of its overall sales.
Palantir's Huge Rally Turns the Tables on Short Sellers: $3 Billion Loss
Soft jobs numbers like these used to start the rate-cut conversation, but this Fed is already looking to raise, and soon
Lynch's run from 1977 to 1990 is viewed as one of the best ever.
AI networking demand keeps accelerating. But how much of it is already in the stock's price?
Baron Capital, an investment management company, released its Q2 2026 investor letter for the “Baron Health Care Fund”. A copy of the letter is available to download here. The Fund gained 11.99% during the quarter, compared with the 10.48% gain for the Russell 3000 Health Care Index and the 15.44% gain for the Russell 3000 Index. Since inception, […]
Sen. Elizabeth Warren (D-Mass.) said the United States does not invest enough in child care, arguing that taxing ultra-millionaires and billionaires could help make child care more affordable while increasing pay for child care workers. In a video posted on...
Circle Internet Group returned to profit in the second quarter, driven by steady growth in its USDC stablecoin despite a prolonged crypto bear market. The company on Wednesday reported net income of $48 million for the three months ended June 30, up from a net loss of $482 million in the same period last year. Quarterly revenue gained 7% to $701 million from $658 million in the year-ago period.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.
Why investing for the long run, especially if you buy certain popular stocks, could reap huge rewards.